Adoptive cell therapy, particularly CAR T-cell therapy, has marked a revolutionary milestone in the treatment of hematological malignancies and is now making strides in the realm of auto-immune diseases. However, for solid tumors, there remains a substantial path ahead.
This congress will delve into the critical aspects of optimizing adoptive cell therapy. The first segment will explore the host conditions for greater efficacy of adoptive cell therapy. Following this, a dedicated session will focus on T-cell engineering, and lastly, we will examine novel targets for CAR T-cell therapy.
The meeting is designed to provide networking between clinicians, scientists from academic and industrial parterns in the field of cell therapies.
This event will bring together the foremost experts in immunology, oncology, and cellular therapy.
Abstract submissions will open in March 2024
Camille Bigenwald, MD, PhD
Laurie Menger, PhD
![]()
This congress will delve into the critical aspects of optimizing adoptive cell therapy. The first segment will explore the host conditions for greater efficacy of adoptive cell therapy. Following this, a dedicated session will focus on T-cell engineering, and lastly, we will examine novel targets for CAR T-cell therapy.
The meeting is designed to provide networking between clinicians, scientists from academic and industrial parterns in the field of cell therapies.
This event will bring together the foremost experts in immunology, oncology, and cellular therapy.
Abstract submissions will open in March 2024
Camille Bigenwald, MD, PhD
Laurie Menger, PhD
Location
Centre de Recherche des Cordeliers
15 Rue de l'École de Médecine, 75006 Paris, France
15 Rue de l'École de Médecine, 75006 Paris, France
Date & Time
May 30, 2024, 9:00 AM - May 31, 2024 - 2:00 PM
Program
HOST
T cell ENGINEERING
TARGETing tumor antigens
T cell ENGINEERING
TARGETing tumor antigens
Yasmine Belkaid, National Institute of Health, USA; Institut Pasteur, France
TBD
Florent Ginhoux, Gustave Roussy, France
Macrophage ontogeny in tumor microenvironment
Jérôme Galon, Centre des Cordeliers, France
TBD
Cécile Alanio, Institut Curie, France
TBD
Julie Heft, Institut Cochin, France
Macrophage subsets and T cell immunity in breast cancer
Camille Bigenwald, Gustave Roussy, France
Host-dependant mechanisms of resistance to CAR T cells in lymphoma
Michel Sadelain, Memorial Sloan Kettering Cancer Center, USA
TBD
Alexander Marson, University of California San Francisco, USA
TBD
Laurie Menger, Gustave Roussy, France
Advanced T-cell therapy using genome-scale CRISPR screens
Suman Mitra, Lille University Hospital, France
TBD
Rahul Roychoudhuri, University of Cambridge, England
Stemness and maintenance of Treg lineage
Justin Eyquem, University of California San Francisco, USA
AAV: efficient genetic engineering of murine T cells
Claire Roddie, University College London, UK
AKT inhibiton to enhance polyfunctional CAR-T cell
Luca Gattinoni, Liebniz Institute for Immunotherapy, Germany
Boosting T cell-based immunotherapies by mitochondrial transfer
Robert Majzner, Stanford & Harvard, USA
TBD
Katy Rezvani, MD Anderson Cancer Center, USA
TBD
Sebastian Amigorena, Institut Curie, France
Epigenetic tumor antigens-JET
Alena Gros, Vall d'Hebron Institute of Oncology, Spain
Personalized T-cell therapies for solid cancers
Organizing Committee: Dr Camille Bigenwald, Dr Laurie Menger et Prof Laurence Zitvogel.
TBD
Florent Ginhoux, Gustave Roussy, France
Macrophage ontogeny in tumor microenvironment
Jérôme Galon, Centre des Cordeliers, France
TBD
Cécile Alanio, Institut Curie, France
TBD
Julie Heft, Institut Cochin, France
Macrophage subsets and T cell immunity in breast cancer
Camille Bigenwald, Gustave Roussy, France
Host-dependant mechanisms of resistance to CAR T cells in lymphoma
Michel Sadelain, Memorial Sloan Kettering Cancer Center, USA
TBD
Alexander Marson, University of California San Francisco, USA
TBD
Laurie Menger, Gustave Roussy, France
Advanced T-cell therapy using genome-scale CRISPR screens
Suman Mitra, Lille University Hospital, France
TBD
Rahul Roychoudhuri, University of Cambridge, England
Stemness and maintenance of Treg lineage
Justin Eyquem, University of California San Francisco, USA
AAV: efficient genetic engineering of murine T cells
Claire Roddie, University College London, UK
AKT inhibiton to enhance polyfunctional CAR-T cell
Luca Gattinoni, Liebniz Institute for Immunotherapy, Germany
Boosting T cell-based immunotherapies by mitochondrial transfer
Robert Majzner, Stanford & Harvard, USA
TBD
Katy Rezvani, MD Anderson Cancer Center, USA
TBD
Sebastian Amigorena, Institut Curie, France
Epigenetic tumor antigens-JET
Alena Gros, Vall d'Hebron Institute of Oncology, Spain
Personalized T-cell therapies for solid cancers
Organizing Committee: Dr Camille Bigenwald, Dr Laurie Menger et Prof Laurence Zitvogel.
